Leap Therapeutics (LPTX) Lifted to Sell at ValuEngine

ValuEngine upgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a strong sell rating to a sell rating in a report issued on Thursday.

Separately, Zacks Investment Research upgraded Leap Therapeutics from a hold rating to a buy rating and set a $7.00 price target for the company in a report on Wednesday, January 3rd.

How to Become a New Pot Stock Millionaire

Shares of Leap Therapeutics stock opened at $8.54 on Thursday. The company has a market capitalization of $105.50, a PE ratio of -2.43 and a beta of 1.10. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $9.36.

A hedge fund recently bought a new stake in Leap Therapeutics stock. Sabby Management LLC bought a new position in shares of Leap Therapeutics Inc (NASDAQ:LPTX) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned 0.72% of Leap Therapeutics as of its most recent filing with the SEC. 3.25% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3300732/leap-therapeutics-lptx-lifted-to-sell-at-valuengine.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

eMagin  Sees Large Decline in Short Interest
eMagin Sees Large Decline in Short Interest
Alio Gold  Sees Significant Growth in Short Interest
Alio Gold Sees Significant Growth in Short Interest
J C Penney Company Inc  Given Consensus Recommendation of “Hold” by Brokerages
J C Penney Company Inc Given Consensus Recommendation of “Hold” by Brokerages
FY2018 EPS Estimates for Royal Dutch Shell Lifted by Analyst
FY2018 EPS Estimates for Royal Dutch Shell Lifted by Analyst
TransAct Technologies  to Release Earnings on Thursday
TransAct Technologies to Release Earnings on Thursday
FY2018 Earnings Estimate for Unilever  Issued By Jefferies Group
FY2018 Earnings Estimate for Unilever Issued By Jefferies Group


© 2006-2018 Ticker Report. Google+.